Whalesbook
FDA Ne Di Lupin Ko Green Signal!
Dekho bhaiyo, US FDA ne Lupin Limited ko unke generic Sugammadex injection ke liye tentative approval de diya hai. Matlab Lupin ki application ne saare scientific aur quality checks clear kar liye hain. Ab bas kuch final permissions, jaise patent aur exclusivity wale issues solve hone hain, aur Lupin America ke anesthesia market mein entry maarega. Investors bhi Lupin ke pipeline progress se khush hain.
Merck Ki Bridion Ko Khatra!
Merck & Co. ka Bridion, jo neuromuscular blockade reversal ke liye use hota hai, uski Q4 2025 mein sales $449 million thi. Lekin ab generic entry ka pressure aa gaya hai. Bridion ke U.S. patents expire ho gaye hain, aur ab Hikma Pharmaceuticals jaise competitors pehle se hain. U.S. mein generic sterile injectable market toh bohot bada hai, $23.6 billion (2025) se $48.0 billion (2034) tak pahunchega. Lupin ka market cap lagbhag ₹1.07 lakh crore hai, toh yeh approval unke liye ekdum perfect hai.
Aage Kya Challenges Hain?
Lekin itna aasan bhi nahi hai. Lupin ko abhi bhi Merck ke patents aur potential patent cases se ladna padega. Kab market mein entry milegi, woh sab patent issues solve hone par depend karega. Generic drugs aksar original drugs ki prices ko significant girate hain, toh ho sakta hai Lupin ka profit bhi kam ho, bhale hi market share mile. Merck ka Bridion revenue mid-2026 se hi kam hone ki umeed hai. Lupin ko price, solid supply chain, aur quality manufacturing pe full focus karna padega, kyunki sterile injectables market mein shortages aam hain.
Analysts Kya Kehte Hain?
Analysts ka Merck ke liye sentiment mostly 'Buy' hai, price targets $124.62 se $127.13 hain. Lupin ke liye 'Outperform' ya 'Buy' ka consensus hai, price targets ₹2,423 ke aas paas hain. Pharmaceutical sector, especially generic injectables, toh growth mode mein hai, kyunki healthcare costs badh rahe hain aur log bhi budhe ho rahe hain. Lupin ka complex generics aur sterile injectables mein focus isi trend ko pakad raha hai.